Full text is available at the source.
Abstract
Over 60% of the target G:C was converted to A:T, significantly increasing FIX activity.
- Cytosine base editing was used to introduce a gain-of-function variant in blood coagulation factor IX (FIX).
- The engineered R338Q variant notably enhanced coagulation factor activity.
- In HEK293 cells with patient-derived F9 variants, increased FIX activity was observed after base editing.
- Knock-in mice carrying human F9 cDNA also showed an increase in FIX activity following treatment.
- Lipid nanoparticles containing the base editor mRNA and gRNA further boosted FIX activity in mice.
- Cytosine base editing for R338Q in FIX may serve as a scalable therapeutic approach for hemophilia B.
Simplified